Metabolic concerns associated with antiepileptic medications

Neurology

Volumn 63, Issue 10 SUPPL. 4, 2004, Pages

  Sheth, Raj D ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Department of Neurology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; ENZYME INHIBITION; EPILEPSY; FRACTURE; HUMAN; KIDNEY CALCIFICATION; LONG TERM CARE; METABOLIC ACIDOSIS; METABOLIC DISORDER; NEPHROLITHIASIS; OSTEOMALACIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

EID: 8844264414     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.10_suppl_4.s24     Document Type: Review

References (63)

1. Acharya JN, Satishchandra P, Shankar SK. Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 1995;36:429-434.
2. Lothman E. The biochemical basis and pathophysiology of status epilepticus. Neurology 1990;40(suppl 2):13-23.
3. Boggs JG. Seizures in medically complex patients. Epilepsia 1997;38(suppl 4):S55-59.
4. Sheth RD: Bone health in epilepsy. Lancet Neurol 2004;3:516.
5. Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999;99:269-275.
6. Sheth RD. Bone health in epilepsy. Epilepsia 2002;43:1453-1454.
7. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(suppl):505S-511S.
8. Poole KE, Reeve J, Warburton EA. Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke 2002;33:1432-1436.
9. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004;5(suppl 2):S36-40.
10. Gidal BE, Sheth RD. Epilepsy and bone health: is there cause for concern? Epilepsy Behav 2004;5(suppl 2):1-2.
11. Sheth RD, Hobbs GR, Riggs JE, Penney S. Bone mineral density in geographically diverse adolescent populations. Pediatrics 1996;98:948-951.
12. Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5(suppl 2):S41-47.
13. Hahn TJ, Hendin BA, Scharp CR, Haddad JG Jr. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972;287:900-904.
14. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002;59:781-786.
15. Pack AM, Morrell MJ. Treatment of women with epilepsy. Semin Neurol 2002;22:289-298.
16. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-1492.
17. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262.
18. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57:445-449.
19. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-1353.
20. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369-1374.
21. Aronne LJ. Classification of obesity and assessment of obesity-related health risks. Obes Res 2002;10(suppl 2):105S-115S.
22. National Center for Health Statistics. Health, United States, 2003. Hyattsville, Maryland: 2003. DHHS Publication No. 2003-1232.
23. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metab Clin North Am 2003;32:1005-1024.
24. Aronne LJ. Obesity as a disease: etiology, treatment, and management considerations for the obese patient. Obes Res 2002;10(suppl 2):95S-96S.
25. Prabhakaran D, Anand SS. The metabolic syndrome: an emerging risk state for cardiovascular disease. Vasc Med 2004;9:55-68.
26. Nelson TL, Palmer RF, Pedersen NL. The metabolic syndrome mediates the relationship between cynical hostility and cardiovascular disease. Exp Aging Res 2004;30:163-177.
27. Sheth RD. Adolescent issues in epilepsy. J Child Neurol 2002;17(suppl 2):2S23-27.
28. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-1529.
29. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17:781-791.
30. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
31. Gidal BE, Anderson GW, Spencer NW, et al. Valproate-associated weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy. J Epilepsy 1996;9:234-241.
32. Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
33. Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55:729-732.
34. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-771.
35. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 1994;57:682-687.
36. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic add: a retrospective study. Can J Neurol Sci 1997;24:240-244.
37. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine-a reappraisal. Seizure 1997;6:121-125.
38. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001;21:904-919.
39. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19:394-396.
40. Arroyo S, Anhut H, Kugler AR, et al., for the Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-27.
41. Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000;9:112-118.
42. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000;54:973-975.
43. Gidal BE, Sheth RD, Magnus L, Herbeuval AF. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003;56:121-126.
44. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53:S53-67.
45. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69.
46. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-244,
47. Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-495.
48. Bourgeois BF. Felbamate. Semin Pediatr Neurol 1997;4:3-8.
49. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11:556-562.
50. Gilliam F, Hecimovic H, Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 2003;4(suppl 4):S26-30.
51. Marquez AV, Farias ST, Apperson M, et al. Psychogenic nonepileptic seizures are associated with an increased risk of obesity. Epilepsy Behav 2004;5:88-93.
52. Izzedine H, Launay-Vacher V, Deray G. Topiramate-induced renal tubular acidosis. Am J Med 2004;116:281-282.
53. Ikeda K, Iwasaki Y, Kinoshita M, et al. Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. Intern Med 2002;41:743-745.
54. Elinav E, Ackerman Z, Gottehrer NP, Heyman SN. Recurrent life-threatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis. Ann Emerg Med 2002;40:259-260.
55. Ozawa H, Azuma E, Shindo K, et al. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur J Pediatr 2001;160:321-322.
56. Inoue T, Kira R, Kaku Y, et al. Renal tubular acidosis associated with zonisamide therapy. Epilepsia 2000;41:1642-1644.
57. Ballaban-Gil K, Callahan C, O'Dell C, et al. Complications of the ketogenic diet. Epilepsia 1998;39:744-748.
58. Bell NH, Key LL Jr. Acquired osteomalacia. Curr Ther Endocrinol Metab 1994;5:495-499.
59. Topamax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; August 2004.
60. Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-747.
61. Zonegran [package insert]. San Diego, Calif: Elan Biopharmaceuticals; 2003.
62. Kossoff EH, Pyzik PL, Furth SL, et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 2002;43:1168-1171.
63. Maydell BV, Wyllie E, Akhtar N, et al. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatr Neurol 2001;25:208-212.